Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development

Journal of Immunology

Volumn 190, Issue 11, 2013, Pages 5588-5599

  Ma, Yunfeng ^a,b   Xiang, Dong ^a,b,c   Sun, Jinwen ^a,d   Ding, Chuanlin ^a,b   Liu, Min ^a,b   Hu, Xiaoling ^a   Li, Guoxin ^e   Kloecker, Goetz ^b   Zhang, Huang Ge ^a,b   Yan, Jun ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c University of Missouri   (United States)

^d Beijing Meitan General Hospital   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD19 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BREAST CARCINOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE MODEL; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; TH2 CELL; TUMOR IMMUNOLOGY; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD19; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; EPITOPES; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; NEOPLASMS; PROTEIN BINDING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TH2 CELLS; TUMOR BURDEN;

EID: 84878038036     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203216     Document Type: Article

References (46)

1. Kirkwood, J. M., L. H. Butterfield, A. A. Tarhini, H. Zarour, P. Kalinski, and S. Ferrone. 2012. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 62: 309-335.
2. Schlom, J. 2012. Therapeutic cancer vaccines: current status and moving forward. J. Natl. Cancer Inst. 104: 599-613.
3. Kantoff, P.W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, et al IMPACT Study Investigators. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363: 411-422.
4. Krug, L. M., G. Ragupathi, C. Hood, C. George, F. Hong, R. Shen, L. Abrey, H. J. Jennings, M. G. Kris, and P. O. Livingston. 2012. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol. Immunother. 61: 9-18.
5. Tacken, P. J., I. J. de Vries, R. Torensma, and C. G. Figdor. 2007. Dendritic-cell immunotherapy: fromex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7: 790-802. (Pubitemid 47480309)
6. Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H. W. Lee, C. G. Park, et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111. (Pubitemid 46196991)
7. Weiner, L. M., J. C. Murray, and C. W. Shuptrine. 2012. Antibody-based immunotherapy of cancer. Cell 148: 1081-1084.
8. Ferris, R. L., E. M. Jaffee, and S. Ferrone. 2010. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28: 4390-4399.
9. Constant, S. L. 1999. B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J. Immunol. 162: 5695-5703. (Pubitemid 29314919)
10. Guo, K., J. Li, J. P. Tang, C. P. Tan, C. W. Hong, A. Q. Al-Aidaroos, L. Varghese, C. Huang, and Q. Zeng. 2011. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci. Transl. Med. 3: 99ra85.
11. Heit, A., K. M. Huster, F. Schmitz, M. Schiemann, D. H. Busch, and H. Wagner. 2004. CpG-DNA aided cross-priming by cross-presenting B cells. J. Immunol. 172: 1501-1507. (Pubitemid 38116793)
12. DiLillo, D. J., K. Yanaba, and T. F. Tedder. 2010. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J. Immunol. 184: 4006-4016.
13. de Visser, K. E., L. V. Korets, and L. M. Coussens. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
14. Fujimoto, M., Y. Fujimoto, J. C. Poe, P. J. Jansen, C. A. Lowell, A. L. DeFranco, and T. F. Tedder. 2000. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13: 47-57.
15. Carter, R. H., and D. T. Fearon. 1992. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256: 105-107.
16. Yan, J., M. J. Wolff, J. Unternaehrer, I. Mellman, and M. J. Mamula. 2005. Targeting antigen to CD19 on B cells efficiently activates T cells. Int. Immunol. 17: 869-877. (Pubitemid 41417954)
17. Ding, C., L. Wang, J. Marroquin, and J. Yan. 2008. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood 112: 2817-2825.
18. Baselga, J., and S. M. Swain. 2009. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9: 463-475.
19. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792. (Pubitemid 32222155)
20. Berns, K., H. M. Horlings, B. T. Hennessy, M. Madiredjo, E. M. Hijmans, K. Beelen, S. C. Linn, A. M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, et al. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402. (Pubitemid 47539306)
21. Shattuck, D. L., J. K. Miller, K. L. Carraway, III, and C. Sweeney. 2008. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68: 1471-1477. (Pubitemid 351346855)
22. Zhang, S., W. C. Huang, P. Li, H. Guo, S. B. Poh, S. W. Brady, Y. Xiong, L. M. Tseng, S. H. Li, Z. Ding, et al. 2011. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17: 461-469.
23. Whittington, P. J., M. P. Piechocki, H. H. Heng, J. B. Jacob, R. F. Jones, J. B. Back, and W. Z. Wei. 2008. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res. 68: 7502-7511.
24. Fleck, L. M. 2006. The costs of caring: Who pays? Who profits? Who panders? Hastings Cent. Rep. 36: 13-17. (Pubitemid 44047568)
25. Radkevich-Brown, O., J. Jacob, M. Kershaw, and W. Z. Wei. 2009. Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Res. 69: 212-218.
26. Benedict, C. A., A. J. MacKrell, and W. F. Anderson. 1997. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J. Immunol. Methods 201: 223-231. (Pubitemid 27086719)
27. Li, B., D. J. Allendorf, R. Hansen, J. Marroquin, C. Ding, D. E. Cramer, and J. Yan. 2006. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J. Immunol. 177: 1661-1669. (Pubitemid 44092502)
28. Solly, K., X. Wang, X. Xu, B. Strulovici, and W. Zheng. 2004. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev. Technol. 2: 363-372. (Pubitemid 39276278)
29. Gilliland, L. K., N. A. Norris, H. Marquardt, T. T. Tsu, M. S. Hayden, M. G. Neubauer, D. E. Yelton, R. S. Mittler, and J. A. Ledbetter. 1996. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 47: 1-20. (Pubitemid 26048776)
30. Prechl, J., D. C. Baiu, A. Horváth, and A. Erdei. 2002. Modeling the presentation of C3d-coated antigen by B lymphocytes: enhancement by CR1/2-BCR coligation is selective for the co-ligating antigen. Int. Immunol. 14: 241-247. (Pubitemid 34213635)
31. Ye, Z., I. Hellström, M. Hayden-Ledbetter, A. Dahlin, J. A. Ledbetter, and K. E. Hellström. 2002. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat. Med. 8: 343-348. (Pubitemid 34407028)
32. Baselga, J., L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58: 2825-2831. (Pubitemid 28311914)
33. Cho, H. S., K. Mason, K. X. Ramyar, A. M. Stanley, S. B. Gabelli, D. W. Denney, Jr., and D. J. Leahy. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760. (Pubitemid 36227628)
34. Charalambous, A., M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman. 2006. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J. Immunol. 177: 8410-8421. (Pubitemid 44893803)
35. Idoyaga, J., A. Lubkin, C. Fiorese, M. H. Lahoud, I. Caminschi, Y. Huang, A. Rodriguez, B. E. Clausen, C. G. Park, C. Trumpfheller, and R. M. Steinman. 2011. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl. Acad. Sci. USA 108: 2384-2389.
36. Caminschi, I., A. I. Proietto, F. Ahmet, S. Kitsoulis, J. Shin Teh, J. C. Lo, A. Rizzitelli, L. Wu, D. Vremec, S. L. van Dommelen, et al. 2008. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273.
37. Melchers, M., I. Bontjer, T. Tong, N. P. Chung, P. J. Klasse, D. Eggink, D. C. Montefiori, M. Gentile, A. Cerutti, W. C. Olson, et al. 2012. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J. Virol. 86: 2488-2500.
38. Steinman, R. M. 2012. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30: 1-22.
39. Vanden Bush, T. J., C. M. Buchta, J. Claudio, and G. A. Bishop. 2009. Cutting Edge: importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes. J. Immunol. 183: 4833-4837.
40. Romond, E. H., E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, Jr., N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353: 1673-1684. (Pubitemid 41464706)
41. Nahta, R. 2012. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr. Med. Chem. 19: 1065-1075.
42. Nahta, R., and R. M. O'Regan. 2012. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res. Treat. 135: 39-48.
43. Whittington, P. J., O. Radkevich-Brown, J. B. Jacob, R. F. Jones, A. M. Weise, and W. Z. Wei. 2009. Her-2 DNA versus cell vaccine: immunogenicity and antitumor activity. Cancer Immunol. Immunother. 58: 759-767.
44. Wang, B., N. Zaidi, L. Z. He, L. Zhang, J. M. Kuroiwa, T. Keler, and R. M. Steinman. 2012. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res. 14: R39.
45. Rawlings, D. J., M. A. Schwartz, S. W. Jackson, and A. Meyer-Bahlburg. 2012. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12: 282-294.
46. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88. (Pubitemid 29241119)